Published in Drug Week, November 26th, 2004
These assets primarily consist of the use of trademarks, U.K. and European governmental marketing authorizations, distribution agreements, and other intangible assets relating to the sale of Periostat in the U.K. and Europe. Sales of Periostat in the U.K. and Europe were approximately $560,000 for the year ended December 31, 2003. The sale of its U.K. and European dental assets reflects a strategic decision by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.